BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29128025)

  • 21. Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.
    Pegoraro F; Favre C
    Ann Hematol; 2021 Apr; 100(4):865-878. PubMed ID: 33547921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-Cell Posttransplant Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Systemic Review.
    Jiang C; Huang J; Shao J; Yang T; Zhao Y; Huang M; Yi H; Shi J; Wan L; Chen F; Cao Y; Hu X
    Cell Transplant; 2024; 33():9636897241259722. PubMed ID: 38856035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
    Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD;
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF; Sheng GY; Luan Z
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
    Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
    Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
    Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
    Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ofatumumab for Post-Transplant Lymphoproliferative Disorder.
    Seshadri M; Crane GM; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Mar; 15(1):68-73. PubMed ID: 32413419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia.
    Ruf S; Moser O; Wössmann W; Kreyenberg H; Wagner HJ
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):50-4. PubMed ID: 21178708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012.
    Marinho-Dias J; Lobo J; Henrique R; Baldaque I; Pinho-Vaz C; Regadas L; Branca R; Campilho F; Campos A; Medeiros R; Sousa H
    Mol Med Rep; 2018 Nov; 18(5):4650-4656. PubMed ID: 30221663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients.
    Marques HH; Shikanai-Yasuda MA; dAzevedo LS; Caiaffa-Filho HH; Pierrotti LC; Aquino MZ; Lopes MH; Maluf NZ; Campos SV; Costa SF
    Rev Soc Bras Med Trop; 2014; 47(5):543-6. PubMed ID: 25467252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim HJ; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
    J Korean Med Sci; 2006 Apr; 21(2):259-64. PubMed ID: 16614511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes.
    Lindsay J; Othman J; Heldman MR; Slavin MA
    Curr Opin Infect Dis; 2021 Dec; 34(6):635-645. PubMed ID: 34751183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice.
    Jiménez S
    Clin J Oncol Nurs; 2015 Feb; 19(1):94-8. PubMed ID: 25689655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.
    Rasche L; Kapp M; Einsele H; Mielke S
    Bone Marrow Transplant; 2014 Feb; 49(2):163-7. PubMed ID: 23832092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.
    Kim N; Sohn HJ; Oh JH; Jeon YW; Lee HJ; Cho HI; Chung BH; Yang CW; Kim TG; Cho SG
    Int J Hematol; 2018 May; 107(5):596-603. PubMed ID: 29188583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recipient-derived EBV-positive Monomorphic Plasmacytoma Type Posttransplant Lymphoproliferative Disorder After Allogeneic Stem Cell Transplant for Severe Aplastic Anemia: A Case Report.
    Carden MA; Caltharp S; Yee ME; Haight AE; Westblade LF; Park S
    J Pediatr Hematol Oncol; 2016 Nov; 38(8):e310-e314. PubMed ID: 27403771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of post-transplant lymphoproliferative disorders.
    Llaurador G; McLaughlin L; Wistinghausen B
    Curr Opin Pediatr; 2017 Feb; 29(1):34-40. PubMed ID: 27906865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
    Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
    Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How I treat posttransplant lymphoproliferative disorder.
    Amengual JE; Pro B
    Blood; 2023 Oct; 142(17):1426-1437. PubMed ID: 37540819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.